Answers are grounded in this paper and cite their sources.
We read with great interest the letter by Neumann et al. [1] on the effect of Silibinin in preventing graft infection in a patient with cirrhosis due to chronic hepatitis C (HCV). We obtained the same result in a patient treated with intravenous (i.v.) Silibinin mono-therapy (Legalon SIL®, Rottapharm-Madaus).
No takes yet. Share an insight, caveat, or question.
Beinhardt et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: